Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute liver failure: a review.

Shahid A Khan1, Naina Shah, Roger Williams

  • 1Liver Failure Group, Institute of Hepatology, Division of Medicine, University College London, 69-75 Chenies Mews, London WC1E 6HX, UK.

Clinics in Liver Disease
|September 15, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to: "Agree to disagree; increasing the impact of recommendations formulated through Delphi methodology".

Journal of hepatology·2026
Same author

Consensus versus Outcome-based Definitions of Acute-on-chronic Liver Failure: Implications for Risk Stratification and Case Identification.

Journal of clinical and translational hepatology·2026
Same author

Alpha 2A adrenergic receptor antagonism reduces fibrosis, inflammation and portal hypertension in models of chronic liver disease.

JHEP reports : innovation in hepatology·2026
Same author

Reply to Goldberg and Tapper Refining ACLF diagnosis: Beyond the scorecard.

Journal of hepatology·2026
Same author

Reply to: "Not yet time to A-Tango in redefining acute-on-chronic liver failure".

Journal of hepatology·2026
Same author

Rifaximin in cirrhosis: when therapeutic drift meets antimicrobial stewardship.

The lancet. Gastroenterology & hepatology·2026
Same journal

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.

Clinics in liver disease·2026
See all related articles

Acute liver failure (ALF) remains a significant challenge, rapidly leading to fatal multiorgan failure. This review covers ALF pathophysiology, epidemiology, prognostic markers, and current treatment strategies.

Area of Science:

  • Hepatology
  • Internal Medicine
  • Critical Care Medicine

Background:

  • Acute liver failure (ALF) has been recognized as a distinct clinical entity since the 1950s.
  • Despite advances, ALF poses a significant challenge due to its potential for rapid progression to multiorgan failure and death.
  • Effective intervention is crucial for improving patient outcomes.

Purpose of the Study:

  • To summarize the fundamental pathophysiology of ALF.
  • To compare epidemiological trends of ALF across the United States, United Kingdom, and the Far East.
  • To review current prognostic markers and therapeutic options for managing ALF.

Main Methods:

  • Literature review and synthesis of existing research on ALF.
  • Comparative analysis of epidemiological data from different geographical regions.

Related Experiment Videos

  • Evaluation of prognostic indicators and treatment modalities.

    • Main Results:

    • Understanding of ALF pathophysiology has significantly improved.
    • Epidemiological trends show regional variations.
    • Various prognostic markers and treatment options are available.

    Conclusions:

    • ALF continues to be a critical condition requiring specialized medical attention.
    • Knowledge of pathophysiology, epidemiology, and treatment is essential for effective management.
    • Ongoing research is vital for advancing ALF care and improving survival rates.